The Oncopig model represents an ideal large animal translational cancer modelfor preclinical and co-clinical trials due to our ability to control the induction of tumors and comorbidities both spatially and temporally.
Rapid Screening and Genetic Manipulation
Our panel of Oncopig cancer cell lines, comprising 15 tumor types to date, provides the added benefit of rapid screening of anti-cancer compounds in parallel with human cancer lines. This panel of human and porcine cancer lines provides the benefit of screening cancer drugs across multiple Oncopig and human cell lines to simultaneously confirm their likely efficacy in humans and pigs before advancing to pre- or co-clinical trials. In addition, through the use of state-of-the-art gene-editing technologies, we have the ability to develop genetically defined pig cancer cell lines for screening of targeted therapeutics. Development of pig cancer cell lines harboring clinically relevant driver mutational profiles is currently underway. In addition, custom lines can be created as needed for individual projects.